Adherence to AASLD guidelines for the treatment of hepatocellular carcinoma in clinical practice: Experience of the Bologna Liver Oncology Group

Digestive and Liver Disease

Volumn 46, Issue 6, 2014, Pages 549-555

  Leoni, Simona ^a   Piscaglia, Fabio ^a   Serio, Ilaria ^a   Terzi, Eleonora ^a   Pettinari, Irene ^a   Croci, Luca ^a   Marinelli, Sara ^a   Benevento, Francesca ^a   Golfieri, Rita ^a   Bolondi, Luigi ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Clinical practice; Guidelines applicability; Hepatocellular carcinoma; Personalised treatment

Indexed keywords

ADULT; AGED; ARTICLE; CANCER STAGING; CHEMOEMBOLIZATION; COMORBIDITY; FEMALE; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER RESECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGE; CARCINOMA, HEPATOCELLULAR; CONTRAINDICATIONS; ECHOGRAPHY; ITALY; LIVER NEOPLASMS; MIDDLE AGED; PATHOLOGY; PERSONALIZED MEDICINE; CLINICAL PRACTICE; CONTROLLED STUDY;

ANTINEOPLASTIC AGENT; IRINOTECAN; SORAFENIB;

AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMORBIDITY; FEMALE; GUIDELINE ADHERENCE; HEPATECTOMY; HUMANS; INDIVIDUALIZED MEDICINE; ITALY; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM STAGING; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 84902545472     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2014.02.012     Document Type: Article

References (28)

1. Bruix J., Sherman M. Management of hepatocellular carcinoma. Hepatology 2005, 42:1208-1236.
2. Forner A., Reig M.E., de Lope C.R., et al. Current strategy for staging and treatment: the BCLC update and future prospects. Seminars in Liver Disease 2010, 30:61-74.
3. Llovet J.M., Brú C., Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Seminars in Liver Disease 1999, 19:329-338.
4. Cammà C., Di Marco V., Cabibbo G., et al. Survival of patients with hepatocellular carcinoma in cirrhosis: a comparison of BCLC, CLIP and GRETCH staging systems. Alimentary Pharmacology and Therapeutics 2008, 28:62-75.
5. Bruix J., Sherman M., American Association for the Study of Liver Diseases Management of hepatocellular carcinoma: an update. Hepatology 2011, 53:1020-1022.
6. Bolondi L., Burroughs A., Dufour J.F., et al. Heterogeneity of patients with intermediate (BCLC B) Hepatocellular Carcinoma: proposal for a subclassification to facilitate treatment decisions. Seminars in Liver Disease 2012, 32:348-359.
7. European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. Journal of Hepatology 2012, 56:908-943.
8. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. New England Journal of Medicine 2008, 359:378-390.
9. Kim S.E., Lee H.C., Kim K.M., et al. Applicability of the BCLC staging system to patients with hepatocellular carcinoma in Korea: analysis at a single center with a liver transplant center. Korean Journal of Hepatology 2011, 17:113-119.
10. Cunningham S.C., Tsai S., Marques H.P., et al. Management of early hepatocellular carcinoma in patients with well-compensated cirrhosis. Annals of Surgical Oncology 2009, 16:1820-1831.
11. Chen C.H., Hu F.C., Huang G.T., et al. Applicability of staging systems for patients with hepatocellular carcinoma is dependent on treatment method-analysis of 2010 Taiwanese patients. European Journal of Cancer 2009, 45:1630-1639.
12. Farinati F., Sergio A., Baldan A., et al. Early and very early hepatocellular carcinoma: when and how much do staging and choice of treatment really matter? A multi-center study. BMC Cancer 2009, 9:33.
13. Borzio M., Fornari F., De Sio I., et al. Adherence to American Association for the Study of Liver Diseases guidelines for the management of hepatocellular carcinoma: results of an Italian field practice multicenter study. Future Oncology 2013, 9:283-294.
14. Brandi G., Biasco G., Mirarchi M.G., et al. A phase I study of continuous hepatic arterial infusion of Irinotecan in patients with locally advanced hepatocellular carcinoma. Digestive and Liver Disease 2011, 43:1015-1021.
15. Sangro B., Carpanese L., Cianni R., et al. Survival after yttrium-90 resin microsphere radioembolization of hepatocellular carcinoma across Barcelona clinic liver cancer stages: a European evaluation. Hepatology 2011, 54:868-878.
16. Brandi G., de Rosa F., Bolondi L., et al. Durable complete response of hepatocellular carcinoma after metronomic capecitabine. Tumori 2010, 96:1028-1030.
17. Iavarone M., Cabibbo G., Piscaglia F., et al. Field-practice study of sorafenib therapy for hepatocellular carcinoma: a prospective multicenter study in Italy. Hepatology 2011, 54:2055-2063.
18. Santi V., Buccione D., Di Micoli A., et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. Journal of Hepatology 2012, 56:397-405.
19. Mirici-Cappa F., Gramenzi A., Santi V., et al. Treatments for hepatocellular carcinoma in elderly patients are as effective as in younger patients: a 20-year multicentre experience. Gut 2010, 59:387-396.
20. Tremosini S., Reig M., de Lope C.R., et al. Treatment of early hepatocellular carcinoma: towards personalized therapy. Digestive and Liver Disease 2010, 42:S242-S248.
21. Bargellini I., Sacco R., Bozzi E., et al. Transarterial chemoembolization in very early and early hepatocellular carcinoma patients excluded from curative treatment: a prospective cohort study. European Journal of Radiology 2012, 81:1173-1178.
22. Cabibbo G., Genco C., Di Marco V., et al. Predicting survival in patients with hepatocellular carcinoma treated by transarterial chemoembolisation. Alimentary Pharmacology and Therapeutics 2011, 34:196-204.
23. Golfieri R., Cappelli A., Cucchetti A., et al. Efficacy of selective transarterial chemoembolization in inducing tumor necrosis in small (<5cm) hepatocellular carcinomas. Hepatology 2011, 53:1580-1589.
24. Golfieri R., Renzulli M., Mosconi C., et al. Hepatocellular carcinoma responding to superselective transarterial chemoembolization: an issue of nodule dimension. Journal of Vascular and Interventional Radiology 2013, 24:509-517.
25. Ruzzenente A., Valdegamberi A., Campagnaro T., et al. Hepatocellular carcinoma in cirrhotic patients with portal hypertension: is liver resection always contraindicated. World Journal of Gastroenterology 2011, 17:5083-5088.
26. Cucchetti A., Ercolani G., Vivarelli M., et al. Is portal hypertension a contraindication to hepatic resection. Annals of Surgery 2009, 250:922-928.
27. AISF Expert Panel, AISF Coordinating Committee Position paper of the Italian Association for the Study of the Liver (AISF): the multidisciplinary clinical approach to hepatocellular carcinoma. Italian Association for the Study of the Liver (AISF). Digestive and Liver Disease 2013, 45:712-723.
28. Kudo M., Izumi N., Kokudo N., et al. Management of hepatocellular carcinoma in Japan: Consensus-Based Clinical Practice Guidelines proposed by the Japan Society of Hepatology (JSH) 2010 updated version. Digestive Diseases 2011, 29:339-364.